#Tecfidera

[phonemantra-blog]

Understanding Dimethyl Fumarate: A Versatile Compound Dimethyl Fumarate (DMF) is a chemical compound with a wide range of applications in various industries, from pharmaceuticals to textiles. In this article, we'll delve into the world of DMF, exploring its uses, benefits, and importance in today's world. What Is Dimethyl Fumarate (DMF)? Dimethyl Fumarate, often abbreviated as DMF, is an organic compound with the molecular formula C6H8O4. It is a white, crystalline substance with a slightly sweet odor. DMF is known for its remarkable versatility and is used in different fields due to its unique properties. [caption id="attachment_55657" align="aligncenter" width="2560"] dimethyl fumarate[/caption] The Diverse Applications of Dimethyl Fumarate DMF has found its way into a multitude of industries, each benefiting from its specific properties and functions. Let's explore some of the key applications of DMF: In Pharmaceutical Industry In the pharmaceutical sector, DMF plays a crucial role as an active pharmaceutical ingredient (API) in the formulation of medications. One of its notable applications is in the treatment of multiple sclerosis. In Textile and Fabrics Another prominent use of DMF is in the textile industry, where it acts as a highly effective antimicrobial and anti-fungal agent. Fabrics treated with DMF are more resistant to mold, mildew, and bacterial growth, making them ideal for various applications, including sportswear and outdoor gear. In Electronics and Plastics DMF is a valuable solvent and processing aid in the production of various electronic components and plastics. It aids in the manufacture of polymers, ensuring uniformity and quality in the final products. Safety and Regulatory Aspects of Dimethyl Fumarate While Dimethyl Fumarate (DMF) offers a wide range of benefits across various industries, it's essential to understand the safety measures and regulatory considerations associated with its usage. Safety Precautions When handling DMF, it's crucial to adhere to safety precautions to minimize potential risks: Protective Gear: Wear appropriate protective gear, including gloves and safety goggles, when working with DMF to prevent skin contact and eye irritation. Ventilation: Ensure adequate ventilation in areas where DMF is used to minimize inhalation exposure. Storage: Store DMF in well-sealed containers away from incompatible substances and in a cool, dry place. Regulatory Compliance DMF is subject to various regulatory standards and guidelines, depending on its intended use. It's important to stay compliant with these regulations to ensure safety and quality. Regulatory bodies such as the Food and Drug Administration (FDA) oversee the use of DMF in pharmaceuticals, while environmental agencies monitor its impact on the environment. Future Trends and Research The applications of DMF continue to evolve, driven by ongoing research and technological advancements. Here are some emerging trends and areas of research related to DMF: Sustainable Production Efforts are underway to develop more sustainable methods for the production of DMF, with a focus on reducing environmental impact and resource consumption. Medical Innovations Researchers are exploring new medical applications of DMF beyond multiple sclerosis treatment, including its potential in autoimmune disorders and cancer therapies. Improved Textile Treatments In the textile industry, scientists are working on innovative methods to enhance the durability and effectiveness of DMF-treated fabrics, opening up new possibilities in fashion and sportswear. Frequently Asked Questions (FAQs) About Dimethyl Fumarate (DMF) What is Dimethyl Fumarate (DMF)? DMF is an organic compound with the molecular formula C6H8O4. It is a versatile chemical with applications in various industries. What are the primary uses of DMF? DMF is used in pharmaceuticals, textiles, electronics, and plastics. It's an active pharmaceutical ingredient, an antimicrobial agent in textiles, and a solvent in electronics and plastics manufacturing. How is DMF used in the pharmaceutical industry? DMF is used in the treatment of relapsing forms of multiple sclerosis. It has shown effectiveness in reducing relapse frequency and slowing disease progression. Is DMF safe to handle? DMF should be handled with care. Safety precautions include wearing protective gear, ensuring proper ventilation, and avoiding skin contact and inhalation of vapors. Are there regulatory guidelines for DMF usage? Yes, regulatory bodies like the FDA oversee DMF's usage in pharmaceuticals, and environmental agencies monitor its impact on the environment. What are the emerging trends in DMF research? Research is focusing on sustainable production methods, exploring new medical applications beyond multiple sclerosis, and improving textile treatments using DMF. Can DMF be used in cancer treatment? Ongoing research is exploring DMF's potential in cancer therapies and autoimmune disorders, but more studies are needed to establish its efficacy. Is DMF environmentally friendly? Efforts are underway to make DMF production more sustainable and environmentally friendly. What are the key properties of DMF? DMF is a white crystalline powder with a slightly sweet odor and is sparingly soluble in water. Where can I stay updated on the latest DMF developments? You can stay informed about DMF advancements through scientific journals, industry news, and regulatory agencies' publications. Conclusion: Dimethyl Fumarate (DMF) has cemented its place as a versatile compound with diverse applications across multiple industries. From improving the quality of life for multiple sclerosis patients to enhancing the durability of textiles, DMF continues to impact our lives in meaningful ways.

[telltalebatman]

the fact lenin had severe multiple sclerosis might just be the funniest discovery of my life.

[healthywayrx]

The option to buy generic Tecfidera online alternatives, signifies a monumental step forward in the journey of MS patients. With enhanced accessibility, tailored dosage options, cost-effective solutions, and streamlined processes, online procurement platforms are rewriting the narrative of medication accessibility. Embracing this convenience empowers patients, enabling them to take control of their treatment regimen and ultimately lead fuller, more enriched lives despite the challenges of MS. Embrace the future of healthcare – embark on your online Tecfidera journey today.

[advpharmacy01]

Modernizing Medication: The Benefits of Purchasing Tecfidera Online

In an era where digital innovation is revolutionizing the way we approach daily tasks, it’s no surprise that healthcare is also embracing the digital wave. Purchasing medications online, such as Tecfidera for multiple sclerosis (MS), is quickly gaining traction for its convenience and accessibility. Let’s dive into the myriad benefits of opting for this contemporary method of acquiring medications.

[healthcare-updates-with-sns]

Anti-Inflammatory Drugs Market: Market Trends and Future Outlook 2024-2032

​​The Anti-Inflammatory Drugs Market size was USD 114.78 billion in 2023 and is expected to reach USD 247.71 billion by 2032, growing at a CAGR of 8.92% over the forecast period of 2024-2032. ​

Get Free Sample Report @ https://www.snsinsider.com/sample-request/3389

Regional Analysis:

North America: Dominates the market due to high prevalence of inflammatory diseases and advanced healthcare infrastructure.​

Europe: Significant market share attributed to increasing adoption of biologic therapies.​

Asia-Pacific: Expected to witness rapid growth owing to rising healthcare expenditure and awareness about inflammatory diseases.​

Market Segmentation:

By Drug Class:

Corticosteroids​

Non-steroidal Anti-inflammatory Drugs (NSAIDs)​

Anti-inflammatory Biologics​

By Application:

Rheumatoid Arthritis​

Psoriasis​

Autoimmune Inflammatory Diseases​

Key Players

AbbVie Inc. (Humira, Rinvoq)

Eli Lilly and Company (Olumiant, Taltz)

Johnson & Johnson Services Inc. (Stelara, Remicade)

Hoffmann-La Roche AG (Actemra, MabThera)

AstraZeneca Plc (Fasenra, Symbicort)

Bristol-Myers Squibb (Orencia, Zeposia)

Amgen Inc. (Enbrel, Otezla)

Novartis Pharmaceuticals Corporation (Cosentyx, Ilaris)

GlaxoSmithKline (Nucala, Benlysta)

Pfizer (Xeljanz, Celebrex)

Sanofi (Dupixent, Kevzara)

Merck & Co., Inc. (Indocin, Singulair)

Boehringer Ingelheim (Ofev, Praxbind)

Takeda Pharmaceutical Company (Entyvio, Velcade)

UCB Pharma (Cimzia, Neupro)

Biogen (Tecfidera, Plegridy)

Regeneron Pharmaceuticals (Dupixent, Kevzara)

Sun Pharmaceutical Industries (Mesacol, Ilumya)

Teva Pharmaceuticals (Ajovy, Copaxone)

Almirall S.A. (Skilarence, Ilumetri)

Key Points:

Growing adoption of biologic and targeted therapies is driving market growth.​

High cost of biologic and targeted therapies may hamper market growth.​

North America leads the market due to advanced healthcare infrastructure.​

Asia-Pacific is expected to witness rapid growth due to rising healthcare expenditure.​

Future Scope:

The anti-inflammatory drugs market is poised for significant expansion, driven by advancements in biologic and targeted therapies. These innovations offer more effective treatment options for chronic inflammatory diseases, potentially transforming patient outcomes. However, addressing the high costs associated with these therapies will be crucial to ensure broader accessibility and sustained market growth.​

Conclusion:

The anti-inflammatory drugs market is on a robust growth trajectory, propelled by technological advancements and increasing prevalence of inflammatory diseases. Strategic initiatives focusing on cost reduction and wider accessibility are essential to fully harness the market's potential in the coming years.​

Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Other Related Reports:

Smart Healthcare Market

Optometry Equipment Market

Post Traumatic Stress Disorder Treatment Market

MRI Guided Neurosurgical Ablation Market

[healthcarercmservices]

What Medications Usually Require Prior Authorization?

Prior authorization services is a process in which a healthcare provider must obtain approval from an insurance company before prescribing certain medications. This requirement ensures that the prescribed drug is medically necessary, cost-effective, and appropriate for the patient’s condition.

Practolytics, a trusted leader in healthcare RCM  and prior authorization services, helps healthcare providers streamline this process, reducing administrative burdens and improving patient access to essential medications.

Below is a detailed breakdown of the types of medications that usually require prior authorization and how Practolytics can assist providers in navigating the approval process.

Types of Medications That Usually Require Prior Authorization

1. High-Cost Brand-Name Medications

Many brand-name drugs require prior authorization due to their high cost. Insurance providers may require patients to try lower-cost generic alternatives first.

Examples include:

Humira (adalimumab) – Used for autoimmune diseases like rheumatoid arthritis.

Enbrel (etanercept) – Treats rheumatoid arthritis and psoriasis.

Xeljanz (tofacitinib) – Used for rheumatoid arthritis and ulcerative colitis.

Dupixent (dupilumab) – Treats eczema and asthma.

Ozempic (semaglutide) – A diabetes drug also used for weight management.

With Practolytics, providers can reduce PA delays by ensuring all necessary documentation is submitted correctly and promptly.

2. Specialty Medications

Specialty drugs used for chronic or complex conditions are expensive and require extensive insurance review.

Examples include:

Cancer drugs (Keytruda, Opdivo, Revlimid)

Multiple sclerosis drugs (Ocrevus, Gilenya, Tecfidera)

HIV/AIDS treatments (Biktarvy, Descovy)

Cystic fibrosis medications (Trikafta, Kalydeco)

Since specialty drugs often require additional documentation, Practolytics assists in managing these requests efficiently, minimizing treatment delays.

3. Medications With High Potential for Abuse

To prevent misuse and addiction, controlled substances often require prior authorization.

Examples include:

Opioids (OxyContin, fentanyl, hydrocodone)

ADHD medications (Adderall, Ritalin, Vyvanse)

Benzodiazepines (Xanax, Ativan, Valium)

Sleep medications (Ambien, Lunesta)

By using Practolytics’ automated PA solutions, providers can ensure compliance with regulatory guidelines while expediting approvals.

4. Medications for Off-Label Use

Insurance companies often require PA for medications prescribed outside of their FDA-approved use.

Examples include:

Methotrexate – Used off-label for autoimmune diseases.

Ketamine – Used off-label for depression and pain management.

Low-dose naltrexone (LDN) – Prescribed for fibromyalgia and multiple sclerosis.

Practolytics assists providers in submitting the necessary medical justifications to secure approvals for off-label prescriptions.

5. Cosmetic and Lifestyle Medications

Drugs used for non-medically essential purposes often require PA.

Examples include:

Hair loss treatments (Propecia, Rogaine)

Weight loss medications (Wegovy, Saxenda)

Erectile dysfunction drugs (Viagra, Cialis)

Hormone therapy (testosterone replacement)

With Practolytics, healthcare providers can navigate these approvals by ensuring proper documentation is in place.

6. Biologics and Immunotherapy Drugs

Biologic medications are highly specialized and require thorough insurance approval.

Examples include:

Monoclonal antibodies (Rituxan, Herceptin)

Interleukin inhibitors (Cosentyx, Stelara)

Checkpoint inhibitors (Keytruda, Opdivo)

Practolytics’ dedicated team ensures that PA requests for biologics are processed quickly, preventing disruptions in patient care.

7. Preventive Medications With Limited Coverage

Some preventive medications require PA based on insurance policies.

Examples include:

Shingles vaccine (Shingrix)

HPV vaccine (Gardasil)

Malaria prevention drugs (Malarone, doxycycline)

Hepatitis B treatments (Viread)

Using Practolytics, providers can secure approvals by ensuring that preventive medication requests meet insurance guidelines.

8. Fertility and Reproductive Medications

Fertility treatments often require prior authorization due to their high cost.

Examples include:

Clomid (clomiphene citrate) – Induces ovulation.

Follistim and Gonal-F – Injectable fertility drugs.

IVF-related medications (Menopur, Lupron)

Practolytics simplifies the PA process for fertility drugs, ensuring faster approval times for patients undergoing treatment.

9. Combination Medications

Combination medications often require PA because insurers may prefer patients to take individual components separately.

Examples include:

Duexis (ibuprofen + famotidine)

Treximet (sumatriptan + naproxen)

Advair, Symbicort – Combination inhalers for asthma and COPD.

With Practolytics’ expertise, providers can justify the need for combination drugs and reduce approval wait times.

10. Step Therapy or Alternative Treatment Requirements

Many insurance plans require patients to try lower-cost drugs before approving a more expensive medication.

Examples include:

Metformin before Jardiance or Trulicity (for diabetes)

SSRIs before Spravato (esketamine) for depression

Practolytics helps providers navigate step therapy protocols to ensure patients receive the most effective treatment without unnecessary delays.

How Practolytics Helps Providers Navigate the Prior Authorization Process

Prior authorization can be time-consuming, but Practolytics offers streamlined solutions to reduce administrative burdens and speed up approvals. Here’s how:

1. Automated PA Submissions

Using advanced technology, Practolytics automates prior authorization requests, minimizing manual effort.

2. Real-Time Status Tracking

Providers can track the status of PA requests in real time, ensuring timely approvals.

3. Expert Documentation and Appeals

If a request is denied, Practolytics assists with appeals, providing necessary justifications to insurance companies.

4. Compliance and Insurance Coordination

Practolytics ensures all PA requests comply with payer policies, reducing the risk of claim denials.

Final Thoughts

Prior authorization is a necessary but complex process that can delay patient care if not managed efficiently. By partnering with Practolytics, healthcare providers can streamline PA approvals, reduce paperwork, and improve patient access to essential medications.

For more information on how Practolytics can optimize your prior authorization workflow, visit their website or contact their expert team today!

[biotech-news-feed]

A decision by European regulators to revoke approvals for five generic versions of Biogen's multiple sclerosis medicine helps cement the drug's monopoly there through early 2025. #BioTech #science

[priyanshisingh]

Multiple Sclerosis Treatment Market - Future Growth Prospects for the Global Leaders

The latest market report published by Credence Research, Inc. “Global Multiple Sclerosis Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2028. The global multiple sclerosis treatment market has grown steadily in recent years. It is expected to grow at a CAGR of 4.1% between 2023 and 2030. The market was valued at USD 24.9 Billion in 2022 and is expected to reach USD 32.9 Billion in 2030.

Multiple Sclerosis (MS) is a chronic, autoimmune disorder affecting the central nervous system, presenting diverse symptoms. The study encompasses various therapeutic interventions, market share, regional growth, and challenges the sector currently faces.

Multiple Sclerosis Treatment Market is a dynamic and rapidly evolving sector within the healthcare industry that focuses on finding effective solutions for patients diagnosed with multiple sclerosis (MS). Multiple sclerosis is an autoimmune disease that affects the central nervous system, causing a range of physical and cognitive impairments. As medical knowledge advances, so does the understanding of this complex condition, leading to innovative treatment options. The market encompasses various pharmaceutical drugs that aim to manage symptoms, slow down disease progression, and improve quality of life for MS patients. These treatments often include immunomodulators or disease-modifying therapies designed to modify or suppress the immune response responsible for damaging nerve cells.

Multiple Sclerosis Treatment Market Top Report Findings reveal significant insights into the current state and future prospects of this dynamic healthcare industry. The report highlights key market trends, growth drivers, challenges, and opportunities for stakeholders involved in multiple sclerosis treatment. It emphasizes the growing prevalence of this chronic autoimmune disease worldwide, leading to increased demand for effective treatment options. Additionally, it sheds light on the rising adoption of disease-modifying therapies (DMTs), which are considered the standard treatment approach for managing multiple sclerosis.

MS treatments can be classified into:

Disease-Modifying Therapies (DMTs): These are drugs that alter the course of the disease. As of 2021, there are several DMTs available:

Injectable treatments (e.g., interferon beta products like Avonex, Betaseron, and Copaxone).

Oral treatments (e.g., Tecfidera, Gilenya, Mayzent, and Mavenclad).

Infusion treatments (e.g., Ocrevus, Tysabri, and Lemtrada).

Symptomatic treatments: These do not alter the disease's progression but treat specific symptoms like fatigue, spasticity, or pain. Examples include muscle relaxants and medications for fatigue.

Rehabilitative Services: Physical, occupational, and speech therapy can help manage certain symptoms and improve the quality of life.

Major Players in the Market

The leading companies involved in the development and distribution of MS treatments include Biogen, Novartis, Sanofi, Roche, and Bayer among others.

Browse 190 pages report Multiple Sclerosis Treatment Market By Drug Class (Immunomodulators, Immunosuppressants, Interferons, Others) By Route of administration (Oral, Injectables, Infusions) - Growth, Future Prospects & Competitive Analysis, 2016 – 2030)- https://www.credenceresearch.com/report/multiple-sclerosis-treatment-market

Multiple Sclerosis Treatment Market Growth Factor Worldwide refers to the various factors driving the growth of the market for multiple sclerosis (MS) treatment on a global scale. MS is a chronic autoimmune disease that affects the central nervous system, causing symptoms such as fatigue, difficulty walking, and cognitive problems. The increasing prevalence of MS worldwide has led to significant advancements in its treatment options. One key growth factor is the rising awareness about early diagnosis and prompt intervention, which has resulted in an increased number of patients seeking medical attention at early stages. Additionally, technological innovations have paved the way for more effective therapies and medications specifically targeting MS symptoms and slowing down disease progression.

The growing focus on research and development activities by pharmaceutical companies has also contributed to expanding treatment options available to patients with MS globally. Furthermore, favorable reimbursement policies implemented by governments across several countries have made these treatments more accessible to patients, stimulating market growth further. Lastly, collaborations between healthcare organizations and patient support groups are promoting greater understanding of this complex condition among both healthcare professionals and individuals affected by it - ultimately leading to better diagnosis rates and improved management strategies worldwide.

Market Forecast

While the precise numbers would require the latest reports and data post-2021, the forecast for the MS treatment market generally points towards growth. The factors contributing to this positive trajectory include:

Rising awareness of the disease.

Improved diagnostic tools.

The launch of newer, more effective drugs.

Expansion of markets in emerging economies.

Why to Buy This Report-

The report provides a qualitative as well as quantitative analysis of the global Multiple Sclerosis Treatment Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.

The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.

Major nations in each region with their import/export statistics

The global Multiple Sclerosis Treatment Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.

Browse Full Report: https://www.credenceresearch.com/report/multiple-sclerosis-treatment-market

Visit: https://www.credenceresearch.com/

Related Report: https://www.credenceresearch.com/report/novel-drug-delivery-systems-ndds-market

Related Report: https://www.credenceresearch.com/report/nasal-drug-delivery-technology-market

Browse Our Blog: https://tealfeed.com/multiple-sclerosis-treatment-market-analysis-size-kwvzw

About Us -

Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.

Contact Us:

Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India

[eloisavaldes]

It has been some really rough months health-wise since the heat started in May. I had two MS mini-relapses this Summer, and a whole lot of exacerbations in-between. #Tecfidera is helping me. I have this feeling that if it wasn't for Tecfidera those would be major relapses like 2 years ago. Anyway, this post isn't about MultipleSclerosis, despite the fact that I'm giving you an update on a part of my life. I came here today to say thank you to my friends who've been supporting me, either through donations or other ways, like listening to my rants, asking if I need anything; still asking me out for a drink, etc. It all counts! Thank you! ♥ I also want to thank my friend @ricardjorg who sent me this awesome game that I'll write about later on my blog! 🤗

[transgendergoblinfromspace]

Started a new medics today for my autoimmune disorder and it’s causing exhaustion and flushing out the gate. Excellent 🙃

[advpharmacy01]

The Healthcare Revolution: Why Millions Place their Trust in Online Pharmacies

One of the most significant advantages of choosing ADV-Care Pharmacy is the vast array of medications we offer. We provide both branded and generic Canadian drugs, ensuring that your prescription needs are met with utmost precision. Whether you’re looking to buy specific medication like Premarin or Tecfidera online or a general prescription online, you’ll find it here.

Read more: https://advpharmacy.com/the-healthcare-revolution-why-millions-place-their-trust-in-online-pharmacies/

[koalasaurusface]

My New Years plans

[twodoggarage]

Infusion 13 (30 overall) •▪•▪•▪•▪ #MS #multiplesclerosis #medicine #wednesday #humpday #tecfidera #pandemic #covid19 #coronavirus #washyourhands #wearamask #stayhome #socialdistancing #immunesystem #notahoax (at Neurology Center of New England) https://www.instagram.com/p/CAIhCizABd5/?igshid=ov0z5avc18sx

[alsapem]

Reposted from @minhaesclerose Corona vírus e companhia devem ser, sim, uma preocupação maior pra quem tem esclerose múltipla. Por quê? Muitos tratamentos para EM se utilizam de medicamentos imunossupressores (s��o eles: Tecfidera, Tysabri, Gilenya, Ocrevus, Mabthera, Mavenclad, Aubagio, Azatioprina e Lemtrada). Estes fármacos inibem parte da atividade do sistema de defesa do corpo, para que a bainha de mielina não seja atacada. Com o sistema imunológico enfraquecido, fica mais fácil ceder a infecções mais graves. Além disso, qualquer infecção num paciente com EM pode servir como gatilho para um novo surto. Então devemos redobrar os cuidados, evitando ambientes com aglomerados ou ficar perto de pessoas com sintomas de gripe, além de sempre higienizar as mãos.⁣ ⁣ Fonte: @esclerosemultiplabrasil⁣ ⁣ ⁣ 🇬🇧 Coronavirus and its gang should be a bigger worry to people with multiple sclerosis. Why is that? Many treatments for MS are based on immunosuppressant drugs (these are: Tecfidera, Tysabri, Gilenya, Ocrevus, Mabthera, Mavenclad, Aubagio, Azathioprine and Lemtrada). Those medications inhibit part of the defense system activity, so that the myelin sheath does not get attacked. With a weakened immune system, it's easier to yield to more serious infections. Besides, any infection in an MS pacient may become a trigger to a new relapse. Therefore, we should double our care, avoiding places with many people or staying close to people with symptoms of the flu, not forgetting to always wash our hands.⁣ ⁣ Info: @esclerosemultiplabrasil⁣ ⁣ ⁣ #esclerosemúltipla #doencasautoimunes #doençasraras #doençasinvisiveis #rarediseases #autoimmunediseases #multiplesclerosis #livingwithms #vivendocomem #forçaG35 #mswarrior #msfighter #slowliving #slowlife #healthywayoflife #glutenfree #sugarfree #dairyfree #coronavirus #tecfidera #tysabri #gilenya #ocrevus - #regrann #alsapem #esclerosemultiplalitoralsantista #forçaG35 #famíliaalsapem #esclerosemultipla #esclerOUSADOS #agostolaranjaoanotodo https://www.instagram.com/p/B9PwJtdBRVi/?igshid=fvul18r2ab5b

[intozevilde]

october 11, 2017 || 5:22p:

the top left is a picture of my hair last year before starting my multiple sclerosis medication, the top right picture is my hair about three months after starting my medication, the bottle left picture is my hair about eight months after starting my medication, and the bottom right picture is today which is thirteen months of being on my medication. i’m happy to be doing well and feeling better than i was last year, but i’d give anything to have my thick curly hair back. i used to love being able to wear my hair down with those beachy wavy curls and now i absolutely hate wearing my hair down, it’s so embarrassing. i would never complain again about it being too thick and hot, or frizzy and out of control, i just wish it would go back to how it used to be. the worst part is my hair won’t be like it used to be for my wedding. x #thickcurlyhairappreciationpost #ms #multiplesclerosis #tecfidera

[sclerosismultiplex]

Specjaliści: pacjentów z SM należy leczyć jak najszybciej, a terapię planować z rozmysłem

Autor: Marzena Sygut/Rynek Zdrowia   08 listopada 2019 15:04

Prof. Krzysztof Selmaj; FOT. PTWP

– U chorego na stwardnienie rozsiane (SM) nie możemy opóźniać leczenia, gdyż rezerwa neurologiczna jest ograniczona. Nieleczone SM, we wczesnej fazie choroby, prowadzi do postępującej atrofii mózgu, a w konsekwencji do dalszego rozwoju choroby i postępującej niesprawności - mówili eksperci podczas 8 MS Experts Meeting International w Krakowie (24-25 października 2019 r.).

Neurolodzy zwracali też uwagę na to, że SM to choroba przewlekła, niezwykle nieprzewidywalna w swym przebiegu i odpowiedzi na leczenie, co sprawia, że ciężko jest planować długofalową terapię pacjenta. Trudności w podejmowaniu decyzji terapeutycznych nastręcza fakt, że dziś stosuje się coraz większą liczbę opcji leczenia SM i parametrów pomiaru rezultatów terapii, co sprawia, że zmiana terapii staje się nie tylko możliwa, ale często obserwowana.

Opóźnienie leczenia szkodzi choremu

Prof. Przemysław Nowacki, kierownik Katedry i Kliniki Neurologii PUM wyjaśnił, że dziś żaden neurolog nie ma już najmniejszej wątpliwości, że terapię u chorych na SM należy wdrażać jak najszybciej. Takie wnioski płyną zarówno z badań klinicznych, jak i codziennej praktyki medycznej prowadzonej w Polsce i na świecie.

– Leki modyfikujące przebieg choroby, jaką jest SM, przede wszystkim hamują zapalenie, które dominuje we wczesnych fazach choroby. Niewyhamowany proces zapalny doprowadza do wczesnego, nieodwracalnego uszkodzenia neuronów a tym samym do niepełnosprawności pacjenta – podkreślił prof. Nowacki.

Dodał, że już badania Kinkel RP i wsp. z 2011 roku pokazują, że jeśli wcześnie, zaraz po wystąpieniu pierwszych objawów, zastosujemy lek modulujący przebieg choroby, w tym wypadku interferon beta 1a, to po dziesięciu latach o 39 proc. mniej pacjentów przejdzie konwersję do klinicznie pewnego stwardnienia rozsianego (clinically definite multiple sclerosis - CDMS).

– Kolejne badania i obserwacje tylko potwierdziły to spostrzeżenia, np. badania nad fumaranem dimetylu zaprezentowane podczas ECTRIMS w 2013 r. pokazały, że u nowo zdiagnozowanych pacjentów leczonych wyjściowo fumaranem dimetylu zmniejsza się w sposób istotny roczny wskaźnik rzutów, jeśli lek zastosowano odpowiednio wcześnie. Analogicznie, zmniejsza się ryzyko wystąpienia niepełnosprawności w tej grupie chorych.

– Jeśli u nowo zdiagnozowanych chorych zastosowano fumaran dimetylu wcześnie to ryzyko progresji niepełnosprawności po dwóch latach było niższe o 71 proc. – wyjaśnił prof. Nowacki.

Podkreślił też, że dostępne dane wskazują jednoznacznie, że opóźnienie leczenia od momentu rozpoznania SM jest skorelowane ze zwiększonym ryzykiem nieodwracalnej progresji choroby o pięć procent w skali roku.